PRGO vs. CORT, SUPN, PCRX, JAZZ, ALKS, CRNX, NUVL, ALPN, INSM, and MDGL
Should you be buying Perrigo stock or one of its competitors? The main competitors of Perrigo include Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Jazz Pharmaceuticals (JAZZ), Alkermes (ALKS), Crinetics Pharmaceuticals (CRNX), Nuvalent (NUVL), Alpine Immune Sciences (ALPN), Insmed (INSM), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "pharmaceutical preparations" industry.
Corcept Therapeutics (NASDAQ:CORT) and Perrigo (NYSE:PRGO) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, community ranking, media sentiment, valuation, risk, analyst recommendations and institutional ownership.
Corcept Therapeutics has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500.
Corcept Therapeutics has a net margin of 22.38% compared to Corcept Therapeutics' net margin of -0.17%. Perrigo's return on equity of 24.19% beat Corcept Therapeutics' return on equity.
Perrigo received 239 more outperform votes than Corcept Therapeutics when rated by MarketBeat users. However, 70.62% of users gave Corcept Therapeutics an outperform vote while only 66.75% of users gave Perrigo an outperform vote.
Corcept Therapeutics currently has a consensus price target of $40.10, indicating a potential upside of 42.76%. Perrigo has a consensus price target of $40.67, indicating a potential upside of 36.33%. Given Perrigo's higher probable upside, analysts clearly believe Corcept Therapeutics is more favorable than Perrigo.
In the previous week, Corcept Therapeutics had 6 more articles in the media than Perrigo. MarketBeat recorded 16 mentions for Corcept Therapeutics and 10 mentions for Perrigo. Perrigo's average media sentiment score of 0.79 beat Corcept Therapeutics' score of 0.67 indicating that Corcept Therapeutics is being referred to more favorably in the media.
Corcept Therapeutics has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.
93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 95.9% of Perrigo shares are owned by institutional investors. 20.5% of Corcept Therapeutics shares are owned by insiders. Comparatively, 0.7% of Perrigo shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Corcept Therapeutics beats Perrigo on 13 of the 17 factors compared between the two stocks.
Get Perrigo News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRGO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
